Tumour necrosis factor-a (TNF-a) is considered to be involved in the insulin resistance of type 2 diabetes mellitus. The offspring of patients with type 2 diabetes mellitus are at increased risk of developing diabetes and several metabolic abnormalities, but the underlying defects responsible are not known. We studied serum TNF-a levels in 30 healthy non-diabetic offspring of type 2 diabetic parents (group A), and the relationship between TNF-a levels and variables associated with insulin resistance and diabetes. For comparison, 30 healthy offspring of non-diabetic parents (group B) were also studied. The median serum concentration of TNF-a was significantly higher in group A than in group B, 3.5 pg/ml compared with 2.0 pg/ml, respectively. The individuals of group A also had significantly elevated levels of glycosylated haemoglobin, fasting glucose, glucose 2 h after an oral glucose tolerance test and triglycerides. We conclude that serum TNF-a concentration is significantly elevated in non-diabetic offspring of type 2 diabetics and this may predict later impairment of insulin action in these individuals.
Introduction
Tumour necrosis factor-α (TNF-α) is a proinflammatory cytokine produced mainly by monocytes and macrophages. 1 It is implicated in many processes in the body, and in the pathogenesis of septic shock, cancer, rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases and other autoimmune or inflammatory disorders. 2, 3 Recent research also suggests that TNF-α is involved in the insulin resistance of obesity and type 2 diabetes mellitus. The molecular mechanism by which TNF-α induces insulin resistance and type 2 diabetes is not known, but in vitro studies indicate that TNF-α inhibits insulinmediated autophosphorylation of the insulin receptor and decreases the phosphorylation of the insulin receptor substrate-1 in muscle and fat tissue, 4,5 most probably by binding to p55 TNF receptor. 6 Values are means ± SD except for body mass index, for which values are medians (interquartile range).
Tumour necrosis factor-α levels are elevated locally and systemically in insulin-resistant obese rodents, 7 and increased adipose tissue expression of TNF-α has also been found in humans with obesity and insulin resistance. 8 In addition, the expression of TNF-α in skeletal muscle from type 2 diabetic humans is significantly greater than in non-diabetic controls. 9 Circulating TNF-α levels in humans with obesity and impaired glucose tolerance are increased, and correlate with abdominal adiposity. 10 The offspring of patients with type 2 diabetes have a 40 -60% probability of progressing to type 2 diabetes and are at increased risk of developing several metabolic abnormalities, such as insulin resistance, high insulin and pro-insulin levels, low levels of high-density lipoprotein (HDL) cholesterol, microalbuminuria and arterial hypertension. 11 -14 The fundamental defects responsible for the development of type 2 diabetes mellitus and insulin resistance in these individuals are not known, and we found only one clinical study about the role of TNF-α in non-diabetic offspring of patients with type 2 diabetes. 15 The aim of the present study was to compare serum TNF-α levels in non-diabetic offspring of type 2 diabetes patients and in non-diabetic offspring of healthy controls, and to assess the relationship between TNF-α levels and the anthropometric and physiological variables associated with insulin resistance and diabetes.
Patients and methods

PATIENTS
We recruited 30 healthy non-diabetic volunteers (15 males and 15 females, mean age 36.5 years) with at least one type 2 diabetic parent (group A). For comparison, 30 nondiabetic healthy controls (group B), matched for age, sex, ethnic background and body weight, with no family history of diabetes mellitus up to the second generation, were selected from the local population (15 males and 15 females, mean age 39.3 years). Enrolment assessment consisted of physical examination, anthropometric measurements (height, weight, circumference of hips and waist), and blood pressure determination ( Table 1 ).
PROCEDURE
After an overnight fast, blood was taken from an antecubital vein and the following parameters were measured: glucose, total cholesterol, HDL cholesterol, triglycerides, glycosylated haemoglobin (HbA 1c ) and TNF-α serum levels. Serum samples were stored at -70 o C for approximately 2 months.
Tumour necrosis factor-α levels were measured using a commercially available, ultrasensitive enzyme-linked immunosorbent assay (ELISA) kit (Human TNF-α Ultrasensitive, BioSource International Inc., CA, USA). Serum standards (100 µl) and serum samples (50 µl) plus standard diluent buffer (50 µl) were added, in duplicate, to a 96-well plate coated with specific antibodies to TNF-α. A biotinylated monoclonal antibody to TNF-α (50 µl) was added and incubated for 2 h at 37 o C. Streptavidin peroxidase (100 µl) was then added for a 30-min incubation at room temperature. After each incubation, four washes with the proper washing buffer were carried out. Finally, 100 µl stabilized chromogen (tetramethylbenzidine) was added for 30 min at room temperature to allow for colour development. The reaction was stopped by adding 100 µl of Stop Solution. The absorbance of each well was then measured at 450 nm, having blanked the plate reader against a chromogen blank. The plate was read using the Stat Fax 2100 microplate reader (Awareness Technology Inc., FL, USA). The effective upper value of this immunoassay kit is 32 pg/ml. Samples with TNF-α concentrations greater than 32 pg/ml were diluted with standard diluent buffer and re-analysed according to the manufacturer's protocol booklet. The results were multiplied by the appropriate dilution factor. The sensitivity of this TNF-α assay is < 0.09 pg/ml.
The proportion of HbA 1c was assessed using a spectrophotometer (model DCA 2000, Bayer Diagnostics, Germany). Serum concentrations of total cholesterol, triglycerides, HDL cholesterol and glucose were analysed by AU560 photometer (Olympus, NY, USA). Lowdensity lipoprotein (LDL) cholesterol levels were calculated using the Friedewald equation. 16 Body mass index (BMI) was calculated using the formula: weight in kg/(height in m) 2 . We did an oral glucose tolerance test (OGTT) to measure serum glucose levels after a standard glucose (75 g) challenge.
STATISTICAL ANALYSIS
Statistical analysis was done using standard software (V10, SPSS ® for MS Windows). All variables were initially tested for a normal distribution. The data from normally distributed variables are presented as mean ± SD. Non-normally distributed data (BMI, triglycerides, TNF-α, total cholesterol, HbA 1c ) are presented as medians (interquartile range). Comparison of variables between the two groups was evaluated by t-test for normally distributed data or by Mann-Whitney U-test for non-normally distributed data. Serum TNF-α levels were log 10 transformed to normalize distribution, and multiple linear regression analysis was used to examine factors that were associated with variations in TNF-α concentration. The log 10 transformation of serum TNF-α was used as the dependent variable. Glucose, total cholesterol, HDL cholesterol, triglycerides and HbA 1c were used as independent variables. A P-value of < 0.01 was taken as indicating statistical significance.
Results
Four individuals in group A and one in group B had impaired glucose tolerance. Two individuals in each group had impaired fasting serum glucose levels. The terms 'impaired glucose tolerance' and 'impaired fasting serum glucose' are used as defined by the 1997 American Diabetes Association criteria. 17 The offspring of diabetic parents had significantly higher serum levels of TNF-α, HbA 1c , fasting glucose and glucose 2 h after TNF-a levels in non-diabetic offspring an OGTT (Table 2 ) compared with offspring of non-diabetic parents. They also had higher serum triglyceride levels and marginally higher total cholesterol levels, but there was no statistically significant difference between the two groups in HDL and LDL cholesterol concentrations. No statistically significant difference between the serum TNF-α concentrations of men and women was found in either of the groups (data not shown).
The multiple linear regression analysis and Spearman correlation coefficients between serum TNF-α and selected metabolic and anthropometric variables showed that the factors that correlated with variations in TNF-α concentration were diastolic blood pressure, log serum HbA 1c concentration and serum triglyceride concentration, but not glucose, total cholesterol or HDL cholesterol concentrations (Tables 3 and 4 ).
Discussion
In the present study, we found that serum levels of TNF-α were significantly elevated in non-diabetic offspring of type 2 diabetic parents compared with the offspring of nondiabetics. The result remained the same after excluding individuals with impaired fasting glucose and/or impaired glucose tolerance. This finding suggests a possible role of TNF-α in the metabolic abnormalities generally found in offspring of patients with type 2 diabetes mellitus, and suggests that the elevated TNF-α concentrations may predict the impairment of insulin action in these individuals.
Considerable evidence supports the hypothesis that chronic exposure to increased endogenous level of TNF-α may play an aetiological role in the insulin resistance that ultimately leads to type 2 diabetes. Prolonged infusion of TNF-α in rats impairs insulinmediated glucose disposal and insulinstimulated suppression of hepatic glucose output. 18 Similarly, administration of exogenous TNF-α or endotoxin-induced TNF-α increases triglycerides, and free fatty acids through enhanced lipolysis and stimulation of hepatic lipogenesis, 19, 20 which can evoke insulin resistance. 
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It is therefore plausible that reduced in vivo insulin sensitivity might occur as a consequence of systemic exposure to high TNF-α levels. This opinion is supported by animal neutralization studies. Hotamisligil et al. 21 administered a recombinant soluble TNF receptor-immunoglobulin G fusion protein to obese Zucker fa/fa rats and reported amelioration of insulin resistance as well as improvements in insulin, glucose and fatty acid levels. Similarly, in a study by Muto et al. 22 in KK-Ay mice (an obese and insulin-resistant type 2 model) treated with complete Freund's adjuvant (a mineral oil adjuvant containing a mycobacterial component), it was shown that pre-treatment with anti-interleukin-1a and -1b antibodies or anti-TNF-α antibody significantly abrogated the improvement in glucose intolerance induced by the adjuvant.
Other studies, by contrast, demonstrated that TNF-α could decrease blood glucose levels in rodents and improve glucose intolerance due to inhibition of gluconeogenesis and increase in glucose utilization. 23, 24 Ofei et al. 25 reported no effect on insulin sensitivity and glycaemic control after using an engineered human anti-TNF-α antibody in patients with type 2 diabetes. Additionally, Ventre et al. 26 demonstrated that targeted disruption of the TNF-α gene in obese and non-obese mice resulted in reduced body adiposity and triglyceride levels in -/-non-obese mice, but not in substantial protection against insulin resistance. These contradictory data have led to controversy about the role of TNF-α in insulin resistance and diabetes, but might be the result of different experimental conditions. Relatives of patients with type 2 diabetes mellitus are at increased risk of developing diabetes, insulin resistance and several TNF-a levels in non-diabetic offspring metabolic abnormalities of type 2 diabetes. 11 -14 In the present study, we showed that healthy non-diabetic offspring of patients with type 2 diabetes had significantly elevated serum levels of triglycerides, fasting glucose, glucose 2 h after an OGTT and HbA 1c compared with the offspring of nondiabetics. The serum concentration of HbA 1c was positively correlated with that of TNF-α. There were no statistically significant differences in the blood pressure, HDL cholesterol or LDL cholesterol between nondiabetic offspring from parents with type 2 diabetes and those from healthy controls with no family history of diabetes mellitus.
Humphriss et al. 27 proved that relatives of patients with type 2 diabetes who had normal glucose tolerance were more insulin-resistant than were the healthy offspring of nondiabetics, and that these individuals also had decreased C-peptide levels and C-peptide: insulin ratios. Stewart et al. 28 claimed that first-degree relatives of non-insulin-dependent diabetes mellitus patients were heavier and more insulin-resistant and had lower HDL cholesterol concentrations than the controls. The differences in insulin resistance and HDLcholesterol concentrations between the groups were independent of obesity. Berenson et al. 29 also showed that, compared with controls, young Caucasian offspring of type 2 diabetics had significantly increased body fat, blood pressure, fasting blood glucose, insulin, glucagon, insulin:C-peptide ratios and triglycerides. After adjustment for differences in BMI, however, only the 30 showed that offspring of patients with type 2 diabetes have (after adjustment for age, BMI, waist:hip ratio and sex) higher fasting blood glucose and HbA 1c compared with offspring of non-diabetic individuals. The role of TNF-α in the development of insulin resistance and diabetes in these individuals has not been studied adequately. A study of Zinman et al. 10 in a homogeneous native Canadian population with high rates of type 2 diabetes mellitus has shown a positive correlation of circulating TNF-α levels with insulin resistance across a spectrum of glucose tolerance. These data, as well as ours, suggest a possible role for TNF-α in the pathophysiology of insulin resistance, and may indicate that increased serum TNF-α levels are early fundamental abnormalities of type 2 diabetes mellitus. One possible reason for TNF-α elevation is prolonged consumption of a high-fat diet, which leads to extracellular acidification. The low extracellular pH can enhance TNF-α expression, which then inhibits proteintyrosine kinase and protein-tyrosine phosphatase activity on the insulin receptor. 31, 32 A second possible reason may be inability to produce neutralizing antibodies to TNF-α. Jobe et al. 33 reported that a major biological difference between diabetes-prone BioBreeding (BB) rats and diabetes-resistant BB rats is the ability of the diabetes-resistant rats to produce neutralizing IL-1b antibodies. Elevated levels of TNF-α may also be the consequence of an acutephase reaction, on the basis of the theory that type 2 diabetes mellitus is a cytokineassociated acute-phase reaction, and is part of the innate immune response. 34 In conclusion, we have identified elevated TNF-α serum levels, as well as metabolic abnormalities, in non-diabetic healthy offspring of type 2 diabetic parents. These data support the hypothesis that chronic exposure to an elevated endogenous level of TNF-α may play an aetiological role in the insulin resistance that ultimately leads to type 2 diabetes mellitus.
